Boston Family Office LLC held its position in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 4,500 shares of the medical instruments supplier’s stock at the end of the second quarter. Boston Family Office LLC’s holdings in C.R. Bard were worth $1,422,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Glen Harbor Capital Management LLC boosted its position in shares of C.R. Bard by 4.7% in the first quarter. Glen Harbor Capital Management LLC now owns 3,184 shares of the medical instruments supplier’s stock worth $791,000 after buying an additional 144 shares during the period. ProShare Advisors LLC boosted its position in shares of C.R. Bard by 1.6% in the first quarter. ProShare Advisors LLC now owns 245,285 shares of the medical instruments supplier’s stock worth $60,963,000 after buying an additional 3,944 shares during the period. Profund Advisors LLC boosted its position in shares of C.R. Bard by 13.1% in the first quarter. Profund Advisors LLC now owns 2,915 shares of the medical instruments supplier’s stock worth $724,000 after buying an additional 338 shares during the period. Korea Investment CORP boosted its position in shares of C.R. Bard by 17.3% in the first quarter. Korea Investment CORP now owns 53,582 shares of the medical instruments supplier’s stock worth $13,317,000 after buying an additional 7,895 shares during the period. Finally, Speece Thorson Capital Group Inc. boosted its position in shares of C.R. Bard by 2.8% in the first quarter. Speece Thorson Capital Group Inc. now owns 36,616 shares of the medical instruments supplier’s stock worth $9,101,000 after buying an additional 988 shares during the period. 77.14% of the stock is owned by institutional investors and hedge funds.

Shares of C.R. Bard, Inc. (NYSE BCR) opened at 318.20 on Monday. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $323.27. The stock has a market capitalization of $23.12 billion, a PE ratio of 41.77 and a beta of 0.59. The firm has a 50-day moving average of $319.58 and a 200 day moving average of $286.55.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same quarter in the prior year, the business posted $2.54 EPS. C.R. Bard’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities analysts anticipate that C.R. Bard, Inc. will post $11.82 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were paid a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is 13.67%.

COPYRIGHT VIOLATION WARNING: “Boston Family Office LLC Maintains Stake in C.R. Bard, Inc. (BCR)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/21/boston-family-office-llc-maintains-stake-in-c-r-bard-inc-bcr.html.

A number of research analysts have recently weighed in on the stock. Jefferies Group LLC reissued a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. BidaskClub cut shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. C.R. Bard has an average rating of “Hold” and a consensus price target of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.80% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.